• Understand the **scientific mechanisms that control stem cell differentiation** to generate homogenous cell populations which maintain the disease phenotype

• Examine whether **iPS cells** can be a **valid substitution for ESCs** and what their **applications are for safety/toxicity testing**

• Discuss **strategies to promote full maturation of stem cell-derived cell populations** and advance your research efforts

• **Overcome challenges in stem cell production** to make sufficient numbers for drug development

• Learn new approaches to **achieve validation of your assay**

• Harness the potential that iPS cells offer for **individualized safety & efficacy screening**

**Benefits of attending**

**Workshops: 27th March 2012**

A) Developing Reproducible and Scalable Methods to Culture Stem Cells: From the Microwell Plate to the Bioreactor

Jim Beltzer, Consultant, Beltzer Consulting Group

B) Integrating a Chemical Toolbox in Pluripotent Stem Cell Systems to Advance Drug Development Programs: Emphasis on Small Molecule-Mediated Modulation of Cell Fate

Dhruv Sareen, Director & Research Scientist I, iPSC Core Facility, Cedars-Sinai Regenerative Medicine Institute

C) Understanding the Role of Stem Cell Factors and Functions to Aid Drug Discovery Efforts

Ian Phillips, Norris Professor of Life Sciences & Director of the Center for Rare Disease Therapies, Keck Graduate Institute
## Benefits of attending

Understanding complex disease mechanisms. Improving safety assessments. Identifying new drug targets.

Drug developers universally indicate that stem cell-derived models will improve many aspects of the drug development process and save valuable time and money. So the rationale is simple, and the benefits are obvious. But it all comes back to HOW.

How can the scientific and practical challenges be overcome to harness the full potential of stem cells?

The 2nd Stem Cells for Drug Developers meeting will bring together the leading scientists from Pfizer, Harvard University, GlaxoSmithKline, McLean Hospital, Novartis, Genentech, The Whitehead Institute and Merrimack Pharmaceuticals to reveal how they are already using stem cells to add value to their discovery and development programs. Learn, network and discuss how to revolutionize your drug discovery and development efforts using stem cell-derived models.

1. **Novartis, Merrimack Pharmaceuticals** and **Abbott** will discuss how they are building stem cell models for use in drug screening and safety/toxicology assessments to understand the mechanisms of drug induced toxicity.

2. Discover how iPSCs and ESCs can be used in disease research to increase your understanding of molecular disease mechanisms with The Whitehead Institute, McLean Hospital and The Medical College of Wisconsin.

3. **GSK** will outline their strategies to ensure in vitro maturation of iPSC – differentiated cardiomyocytes and **Regeneron Pharmaceuticals** will explore the use of 3D models to enhance functionality and morphology of ESC derived lineages.

4. Find out how **Eli Lilly, Pfizer, Sanofi** and **AVEO Pharmaceuticals** are incorporating stem cells into their drug discovery activities for toxicity evaluation and to develop more predictive cellular assay systems.

5. The **NIH** will discuss how to design a robust and scalable process to manufacture iPSC-derived motor neurons and achieve sufficient numbers for drug development purposes.

6. Learn how to differentiate stem cells more accurately by listening to how **Harvard University** and Wellstat Therapeutics are controlling stem cell fate into desired lineages.

7. Cut through the hype and understand how **Genentech, Pfizer, Novartis** and **GSK** are already benefitting from using iPSCs in the R&D process.

8. Gain valuable insight into how **Johnson & Johnson** is overcoming challenges to validate preclinical and clinical assays and avoid immunological pitfalls in assay development.

## Who should attend?

This meeting has been designed to provide cutting edge insights for drug developers to find the best way to incorporate stem cell-derived models into drug discovery & development. It’s also a fantastic occasion for companies currently focused on stem cell therapy to explore new opportunities and generate revenue in the near-term.

From using stem cells in disease research to safety/toxicology assessment and recent breakthroughs in iPSC cell technology, this meeting is for those involved in:

- Stem cell biology & research
- Drug discovery & development
- Safety & toxicology assessment
- Disease research
- Target identification & validation
- Genetic models
- Regenerative medicine
- Clinical strategy/development
- R&D strategy
- Commercial development

Search groups for Stem Cells for Drug Discovery Forum to join the online community.

---

**Hear what attendees said about our Stem Cells for Drug Developers meeting, April 2011:**

- **“Excellent overview of pharma’s interests and opportunities”**  
  Merck

- **“This was a great event to gain insight into the broad approaches of stem cells in the drug discovery space”**  
  Beckman Coulter

- **“Nicely balanced cross sections of the current state of stem cell applications”**  
  Pfizer

- **“Informative with fantastic networking opportunities, very well organized”**  
  Harvard University

- **“Excellent depth of information on the topic”**  
  Aldagen

- **“Excellent content”**  
  BD Technologies
### Day 1

#### 08.00 Registration, Coffee and Networking

#### 08.55 Chair’s Opening Remarks

**Ole Isacson**, Professor of Neurology, & Director, Center for Neuroregeneration Research, **Harvard Medical School & McLean Hospital**

#### Using Stem Cells To Model Disease

**09.00** iPS Cell Technology and Disease Research: Issues to be Resolved
- Key issues using iPS cells for disease research and therapy including gene targeting
- Quality of iPS and ES cells and reprogramming mechanisms

**Rudolf Jaenisch**, Professor of Biology & Founding Member, **MIT & The Whitehead Institute**

**09.30** New Paradigms for Modeling Neurodegenerative Disease and Treatments with iPS Cells from Parkinson’s Disease Patients
- Genetic and hereditary modeling of neurodegenerative diseases in human neurons in vitro
- Overlapping cellular pathway and organelle dysfunction, with different genotypes causing the same disease
- Rescue of cellular dysfunction by targeted actions of tool compounds

**Ole Isacson**, Professor of Neurology, & Director, Center for Neuroregeneration Research, **Harvard Medical School & McLean Hospital**

**10.00** Modeling Neurodegenerative Diseases in a Dish
- Data identifying molecular mechanisms of motor neuron loss in spinal muscular atrophy (SMA) stem cells
- Data testing therapeutic compounds in SMA stem cells
- Possible complications to using stem cell based assays for neurodegenerative diseases

**Allison Ebert**, Assistant Professor, Department of Cell Biology, **Medical College of Wisconsin**

**10.30** Speed Networking Session and Morning Refreshments

### Overcoming Challenges In Using Stem Cells In Drug Discovery

**12.00** Novel Stem Cell Based Approaches to Modeling Cancer
- Preclinical models for oncology and other disease areas
- Discovery of predictive biomarkers in preclinical models
- Translating preclinical discovery into clinical research

**Joerg Heyer**, Director, Cancer Biology, **AVEO Pharmaceuticals**

**12.30** Integration of Human ESC/iPSC Derived Cells into Drug Discovery
- Imparative for incorporating pluripotent stem cell derived cells into drug discovery and current applications
- Gaps and future directions for use of pluripotent stem cell derived cells in drug discovery

**Sandra Engle**, Senior Principal Scientist, Pluripotent Stem Cell Biology, **Pfizer**

#### 1.00 Small Molecules to Stimulate Endogenous Repair in the Nervous System
- Overview of the remyelination strategy and challenges
- Data from an orally bioavailable, brain penetrable compound
- Stimulation of human oligodendrocyte progenitor cell differentiation in vitro, in a concentration dependent manner

**Karen Chandross**, Director, Early to Candidate Unit, **Sanofi**

**1.30** Lunch and Networking

### Controlling Stem Cell Differentiation Into Desired Lineages

**2.30** Increasing our Understanding of Signaling Pathways Involved in Stem Cell Differentiation to Advance Research Efforts
- Differentiation protocols for ESCs and iPSCs
- Enhancing efficiency of reprogramming

**Lee Rubin**, Professor, Stem Cell & Regenerative Biology, **Harvard University**

**3.00** Directed Differentiation of Stem Cells Co-Cultured with OP9-DL1 Cells into Engraftable T-Progenitors
- OP9-DL1 cells induce the stage-specific differentiation of stem cells into T-lineage cells
- Two human T-progenitor cell populations have been identified that exhibit rapid immune-engraftment within immunodeficient mouse models
- Human T-progenitor cells differentiate into mature functional T cells

**Ross La Motte-Mohs**, Senior Scientist, **Wellstat Therapeutics**

**3.30** Afternoon Refreshments and Networking

**4.00** DNA Methylation Dynamics in Stem Cells and Development
- Methylation dynamics in early development
- Epigenetic variation in stem cells
- Non-CG methylation in stem and differentiated cells
- Epigenetic reprogramming

**Alexander Meissner**, Assistant Professor, **Harvard Stem Cell Institute**

**4.30** Addressing the Gaps in Stem Cell Derived Models to Promote Wider Adoption in this Field
- What are the limitations of current systems and how can stem cells enhance the predictivity of in vitro models?
- Where do the knowledge gaps lie?

**Sandra Engle**, Senior Principal Scientist, Pluripotent Stem Cell Biology, **Pfizer, Gary Gintant**, Senior Group Leader, **Abbott, & Christine Ivashchenko**, Principal Scientist, **GSK**

**5.00** Chair’s Closing Remarks

**7.00** Networking Dinner
Share discussions with your peers and enjoy a relaxing and informal dinner in comfortable surroundings. Good food, good wine, good company!
Day 2

08.00 Registration, Coffee and Networking

08.55 Chair’s Opening Remarks
Gary Gintant, Senior Group Leader, Abbott

Generating Fully Matured Cell Populations

09.00 Strategies to Promote In Vitro Maturation of Stem Cell-Derived Cardiomyocytes
- Functionality of in vitro hiPS-differentiated cardiomyocytes (hiPS-CM)
- Equivalency of hiPS-CM to cells isolated from a mature organ
- Strategies to promote hiPS-CM maturation
Christine Ivashchenko, Principal Scientist, GlaxoSmithKline

09.30 3D Culture Models for Tissue-Specific Stem Cells and Cancer Stem Cells, In Vivo and In Vitro
- VelociGene platform allows for rapidly generating desired genetic modifications in mouse embryonic stem cells
- Genetically modified mouse ES cells can be differentiated into desired lineages using in vitro and in vivo protocols
- 3D culture models act as readouts for modulation of stemness and/or lineage specification
Courtney M Williams, Scientist, Regeneron Pharmaceuticals

Advances In Stem Cell Manufacturing

10.00 Manufacturing Functional Motor Neurons from Human Pluripotent Stem Cells
- Expansion and differentiation of neural cells
- Designing a robust and scalable manufacturing process
Mahendra Rao, Director, Center for Regenerative Medicine, NIH

10.30 Morning Refreshments and Networking

Stem Cells For Drug Screening & Safety/Toxicity Assessment

11.00 Assessing Surrogates of Clinical Cardiotoxicity Using Stem Cell-Derived Cardiomyocytes
- Demonstrate approach to preclinically assess drug safety using stem cell derived models
- Understanding the mechanism of action of drug-induced cardiotoxicity
- Translating preclinical toxicity results to the clinic
Joe Reynolds, Senior Scientist, Merrimack Pharmaceuticals

11.30 High-Throughput Screening Using Stem Cell-Based Models: Turning an Innovative Technology into a Transformative Approach to Drug Design
- Stem cell-based approaches have the potential to revolutionize the practice of medicine

12.00 Lunch and Networking

1.15 Preclinical Assessment of Cardiac Safety/Toxicity Using Stem Cell-Stems: Strengths, Limitations & Future Possibilities
- Advantages of cardiac stem cells in safety/toxicity screening
- Assays and models presently used in pharma
- Integration of stem cells in safety assessments and evolving strategies
- What can we do better?
Gary Gintant, Senior Group Leader, Abbott

Comparing The Utility of ESCs & iPSCs

1.45 What are the Pros and Cons of Using ESCs and iPSCs and What are their Applications for Safety and Toxicity Assessment?
- Advantages and disadvantages of ESCs and iPSCs
- Comparing preclinical predictivity of stem cell-derived models with primary cell models
- Stem cell technology application strategy in drug development: Cardiotoxicity, hematopoietic toxicity and hepatotoxicity
Hirdesh Uppal, Scientist, Genentech

2.15 Afternoon Refreshments and Networking

Ensuring Proper Assay Development

2.45 iPSC-Derived Neurons as a Physiologically Relevant Model for Drug Discovery
- Role of cell models in drug discovery
- Development and validation of an iPS derived neuronal cell model
- Application of iPS derived neuronal models to drug discovery
Jeff Dage, Senior Research Advisor, Eli Lilly

3.15 Developing and Validating Preclinical and Clinical Assays to Measure Immunological Response
- Allogeneic versus xenogeneic modeling
- Preclinical assay development: Learning the immunological pitfalls
- Clinical immunogenicity monitoring
- Considerations for clinical trials
Sicco Popma, Principal Research Scientist, Stem Cell Organization, Johnson & Johnson

3.45 Chair’s Closing Remarks
### Workshop A: Developing Reproducible and Scalable Methods to Culture Stem Cells: From the Microwell Plate to the Bioreactor

The culture of human embryonic stem cells (hESC) has begun to move from the research laboratory toward various clinical applications. These applications include: cell therapies, disease modeling and drug screening. Inherent to all of these applications is the need for reproducible and scalable culture methods that preserve the desirable traits of hESCs such as pluripotency, genetic stability, and growth rates.

Attendees will explore and discuss:

- **Approaches to finding the right culture conditions to meet your needs**
- **Matrix, media and cell line considerations for optimal growth and performance**
- **Drivers for scale up, manufacturing concerns and potential bottlenecks**
- **Bags, bioreactors, micro-carriers, hollow fiber and fixed bed bioreactors**

This course will describe the methods and the metrics that you will need to successfully scale your hESC cultures from microwell plates to multi-liter bioreactors.

### Workshop B: Integrating a Chemical Toolbox in Pluripotent Stem Cell Systems to Advance Drug Development Programs: Emphasis on Small Molecule-Mediated Modulation of Cell Fate

As induced pluripotent stem cells can be differentiated to virtually any tissue in the body, they represent a new source of tissue for recreating human “disease-in-a-dish” models. These cells can address a significant bottleneck in drug development by providing physiologically-relevant functional human cell types in more predictive cellular assay systems. This has resulted in the identification of a multitude of functional small molecules involved in somatic/stem cell fate specification. Attendees will discuss and debate:

- **Current utilization of pluripotent stem cells (PSCs) in drug discovery**
- **Challenges associated with current iPSC technology**
- **Compounds currently involved in modulating PSC fate**
- **Specification of various cell populations from PSCs**
- **Characterizing small molecules using various approaches**

Attendees will leave this workshop with the tools they need to incorporate small molecules into their pluripotent stem cell research to advance their drug development programs.

### Workshop C: Understanding the Role of Stem Cell Factors and Functions to Aid Drug Discovery Efforts

Stem cells not only have the potential to become therapies for disease, but they can also be used in vitro to aid in drug discovery and drug testing, saving companies time and money. Stem cells secrete growth factors that may be the source of their therapeutic effect and studying these factors could lead to new drugs. In addition microRNA regulates stem cells and specific inhibitors of stem cell microRNAs could become new drugs for regulating stem cell genes. This workshop will discuss:

- **In vitro use of human stem cells for drug toxicity studies**
- **Paracrine hormones secreted by stem cells that may become drugs**
- **Antisense (antagomirs) for specific microRNA that regulate stem cells**

Participants will leave this workshop with the knowledge they need to use stem cells to aid their drug discovery efforts.
Speakers

**Rudolf Jaenisch**
Professor of Biology & Founding Member, MIT & The Whitehead Institute

Rudolf Jaenisch is a Founding Member of the Whitehead Institute and a Professor of Biology at MIT. His laboratory is exploring the role of DNA modification, genomic imprinting and the nature of stem cells.

**Karen Chandross**
Director, Early to Candidate Unit, Sanofi

Dr. Chandross supports the Early to Candidate Unit’s efforts to develop stimulators of endogenous tissue repair and global R&D regenerative medicine initiatives. She received her PhD at the Albert Einstein College of Medicine.

**Jeff Dage**
Senior Research Advisor, Eli Lilly

Dr. Dage is a Senior Research Advisor at Eli Lilly and Company. Through his leadership of the stem cell platform team, Dr. Dage is responsible for the evaluation and implementation of stem cell based research across drug discovery.

**Allison Ebert**
Assistant Professor, Department of Cell Biology, Medical College of Wisconsin

Dr. Ebert is an assistant professor in the Department of Cell Biology, Neurobiology and Anatomy at the Medical College of Wisconsin where she uses stem cells to model and potentially treat neurodegenerative diseases.

**Gary Gintant**
Senior Group Leader, Abbott

Gary Gintant is a Research Fellow in the Dept. of Integrative Pharmacology, Abbott Laboratories. He is involved in multiple internal and external drug discovery and safety initiatives, and serves on multiple journal editorial boards.

**Joerg Heyer**
Director, Cancer Biology, AVEO Pharmaceuticals

Dr. Heyer is heading AVEO Pharmaceuticals Genetic Models efforts supporting translational research and biomarker discovery for AVEO Pharmaceuticals drug discovery programs. Dr. Heyer received his Ph.D. at the Julius Maximilians University Wuerzburg.

**Ole Isacson**
Professor of Neurology, & Director, Center for Neuroregeneration Research, Harvard Medical School & McLean Hospital

Important recent scientific discoveries for neurological and psychiatric diseases made in Dr. Isacson’s lab through the use of ES and iPS cells show how to model disease, provide neuroprotection and how degenerated brain cell circuitry and synapses can be restored or replaced.

**Hirdesh Uppal**
Scientist, Genentech

Hirdesh Uppal is a Scientist in Safety Assessment & Development Sciences at Genentech. He is developing cutting edge stem cell technologies to harness the power of iPSCs to transform drug discovery and enable the promise of regenerative medicine.

**Courtney M Williams**
Scientist, Regeneron Pharmaceuticals

Courtney M. Williams is currently a Scientist in the Oncology and Angiogenesis group at Regeneron. Her work focuses on designing and implementing in vitro cell culture systems for cancer stem cell target validation.

**Sandra Engle**
Senior Principal Scientist, Pluripotent Stem Cell Biology, Pfizer

Sandra Engle is a Senior Principal Scientist in the Pluripotent Stem Cell Biology Laboratory within Pfizer. Her lab focuses on generating iPSCs, differentiation of stem cells and the genetic modification of human stem cells.

**Christine Ivashchenko**
Principal Scientist, GlaxoSmithKline

Christine Ivashchenko is a principal scientist at GlaxoSmithKline pharmaceuticals. Her current research focus is on the use of stem-cell derived cardiomyocytes in the discovery of novel heart failure therapeutics.

**Sidney Hirdesh**
Scientist, Stem Cell Organization, Novartis

Sicco Popma is a Principal Research Scientist at the Stem Cell Organization of Johnson & Johnson. He directs preclinical and clinical stem cell immunology, bio-distribution, biomarker and drug delivery research.

**Mahendra Rao**
Director, Center for Regenerative Medicine, NIH

Dr. Rao is internationally renowned for his research involving human embryonic stem cells (hESCs) and other somatic stem cells. He received his Ph.D. in developmental neurobiology from the California Institute of Technology.

**Joe Reynolds**
Senior Scientist, Merrimack Pharmaceuticals

Joe is a Senior Scientist at Merrimack Pharmaceuticals in their Research and Development group working on the clinical candidate MM-302. He received his PhD from Boston University in Molecular, Cellular Biology and Biochemistry.

**Dr. John Dagle**
Senior Research Advisor, Eli Lilly

Joe is a Senior Research Advisor at Eli Lilly and Company. Through his leadership of the stem cell platform team, Dr. Dage is responsible for the evaluation and implementation of stem cell based research across drug discovery.

**Dr. Katya Tsaioun**
CSO, Cyprotex

“The speaker array and order was perfect and allowed me to take the maximal amount of knowledge back to the lab”
Sponsorship opportunities

If your organization needs to raise profile, promote products and services or develop new partnership opportunities in the stem cell sector, contact:

Miles Harley
tel: +44 (0)20 3141 8700
e-mail: miles.harley@hansonwade.com

Working with Hanson Wade

When you work with Hanson Wade you work with a partner focussed on your success. Your investment in both time and money needs to generate a return.

Our clients want that too and that's why they work with us. They want to reach a targeted audience and eliminate wastage from their marketing activities. They work with us because we deliver results. We're proud of this fact.

Our research identifies ground breaking issues and allows you to influence industry thinking at an early stage. Our expertise is recognised and respected by the industry. And our events are focussed, leading edge and attended by people looking for knowledge before making decisions.

Attendee breakdown

Attendee breakdown at the last meeting

- Large Pharma/Biotech: 48%
- Service Provider: 35%
- Academia: 17%

Seniority breakdown at the last meeting

- Scientist/Group Leader/Manager: 51%
- Director: 35%
- Vice President: 14%

Media Partners

Stem Cell Assays
Promoting Rigorous Reproducible Research on Stem Cells

Speaker Organizations

Tel: +44 (0) 203 141 8707   Email: join@hansonwade.com
2nd Stem Cells for Drug Developers  
Boston  
27th-29th March 2012  
Priority Code: DSN

Register

Tel: +44 (0)20 3141 8707  
Email: join@hansonwade.com

Team discounts

- 10% discount – 3 delegates  
- 15% discount – 4 delegates  
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Venue and accommodation

Venue  
DoubleTree Suites by Hilton Hotel Boston  
400 Soldiers Field Road, Boston, Massachusetts, United States 02134-1893, Tel: 1-617-783-0090.

Accommodation  
Accommodation is not included in your fee. You will be sent accommodation options upon registration.

Purchase audio presentations

If you are unable to attend the meeting in person or would like documentation in addition to your attendance you may purchase the audio recordings of the speaker presentations for $799. These will be sent to you on CD rom with all available presentation slides within 10 days of the meeting. Audio orders can only be processed on receipt of credit card details.

Delegate details

Title:  
Forename:  
Surname:  
Job Title:  
Company/Organization:  
Email:  
Direct Manager:  
Address:  
Postcode:  
Country:  
Direct Telephone:  
Mobile:  
Switchboard:  
Signature:  
Date:  

Payment details

Number of delegates  
Amount: $  
Conference Documentation  
Credit Card:  
Visa  
Mastercard  
Amex  

Card No:  
Valid from:  
_EXPIRY_DATE_  
Expiry Date:  
Cardholders name:  
Signature:  
Date:  
Card billing address:

Event prices

<table>
<thead>
<tr>
<th>Package</th>
<th>Register and pay before Friday 20th January*</th>
<th>Register and pay before Friday 10th February*</th>
<th>Standard Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + 3 workshops + Networking Dinner**</td>
<td>$3596 (SAVE $500)</td>
<td>$3696 (SAVE $400)</td>
<td>$3796 (SAVE $300)</td>
</tr>
<tr>
<td>Conference + 2 workshops + Networking Dinner**</td>
<td>$3097 (SAVE $400)</td>
<td>$3197 (SAVE $300)</td>
<td>$3497</td>
</tr>
<tr>
<td>Conference + 1 workshop + Networking Dinner**</td>
<td>$2598 (SAVE $300)</td>
<td>$2698 (SAVE $200)</td>
<td>$2898</td>
</tr>
<tr>
<td>Conference + Networking Dinner**</td>
<td>$2099 (SAVE $200)</td>
<td>$2199 (SAVE $100)</td>
<td>$2299</td>
</tr>
<tr>
<td>Half day workshop</td>
<td>$599</td>
<td>$599</td>
<td>$599</td>
</tr>
</tbody>
</table>

Please select your choice of workshop:  
A ☐  B ☐  C ☐

**To opt out of the networking dinner please tick here.  
$100 will be discounted from your package price.

A 40% discount is available for academics and not for profit organizations, please email info@hansonwade.com for more information or to register.

*All discount offers (including team discounts) require payment at the time of registration to receive any discount. *Early Bird* discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less including the fourteenth day prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJ.

Tel: +44 (0) 203 141 8707  
Email: join@hansonwade.com

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216